11 August 2021: Clinical Research
Outcomes in 36 Patients with Stage IIIA-N2 Squamous Cell Carcinoma of the Lung Treated with Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy: A Prospective Study from a Single Center
Jianquan Zhu 1ABCDEF , Yu Zhang 1BC , Meng Wang 1BC , Zhenfa Zhang 1BC , Dongsheng Yue 1BC , Shichang Liu 2BC , Yi Pan 3BC , Changli Wang 1AE*DOI: 10.12659/MSM.930738
Med Sci Monit 2021; 27:e930738
Figure 4 Survival outcomes by different short-term efficacy endpoints of patients with squamous cell carcinoma of the lung treated with neoadjuvant nab-paclitaxel and carboplatin. (A) PR for OS. (B) PR for PFS. (C) MPR for OS. (D) MPR for PFS. (E) pCR for OS. (F) pCR for PFS. PR – partial response; OS – overall survival; PFS – progression-free survival; MPR – major pathologic response; OS – overall survival; pCR – pathologic complete response; CI – confidence interval; NE – not evaluable; IRC – Independent Reviewer Committee.